Ascending as a new biopharmaceutical force

Vision 20/20


Ascendis Pharma is working towards a number of long-term strategic goals, outlined in a plan called “Vision 20/20.” This plan reflects our mission to create best-in-class rare disease products that address unmet medical needs by utilizing TransCon technology to improve parent drugs with demonstrated clinical proof-of-concept. With this strategy, we are using our technology to develop potentially best-in-class products with improved efficacy, safety and/or convenience. In addition, we believe our technology enables a higher development success rate compared to traditional drug development.

With Vision 20/20, Ascendis plans to:

  • Advance our pipeline of three rare disease endocrinology product candidates—each of which address unmet medical needs and have significant market potential. These products include:
    • TransCon Growth Hormone, currently in Phase 3 clinical development for pediatric growth hormone deficiency, a growth disorder
    • TransCon PTH for hypoparathyroidism, an endocrine deficiency disease
    • TransCon CNP for achondroplasia, a growth disorder and the most common type of dwarfism
  • Seek to obtain regulatory approval for and launch of three product candidates between 2020 and 2024
  • Identify a new rare disease therapeutic area with high-value product opportunities
  • Leverage our pipeline to create a leading integrated commercial business primarily focused on the U.S. market, with best-in-class rare disease products that address unmet needs

TransCon Technology

At the core of our strategic Vision 20/20 is our proprietary TransCon technology. This technology is designed to solve the fundamental limitations of previous approaches applied to extend duration of a drug’s action in the body, and to enhance the overall benefit of a given therapeutic. Learn More